Ignite Creation Date:
2024-05-06 @ 1:48 AM
Last Modification Date:
2024-10-26 @ 11:10 AM
Study NCT ID:
NCT01906632
Status:
COMPLETED
Last Update Posted:
2024-02-07
First Post:
2013-07-21
Brief Title:
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy
Detailed Description:
1 The patients with malignant tumor are treated with dendritic cells DC plus cytokine induced killer cells CIK
2 Venous blood 4 ml is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic AcidEDTA before and after each treatment Lymphocytes are sorted by Fluorescence Activated Cell SortingFACS and stored at -80C until processing
3 The T-Cell ReceptorB-Cell Receptor gene expression is detected by micro-array
4 Estimate Immunotherapy response time to disease progression survival rates and clinical benefit response on patients Response is assessed using Response Evaluation Criteria in Solid Tumor Group RECIST guidelines Degree of response is used to divide the cancers into two groups sensitive and non-sensitive to immunotherapy
5 Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response
2 Venous blood 4 ml is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic AcidEDTA before and after each treatment Lymphocytes are sorted by Fluorescence Activated Cell SortingFACS and stored at -80C until processing
3 The T-Cell ReceptorB-Cell Receptor gene expression is detected by micro-array
4 Estimate Immunotherapy response time to disease progression survival rates and clinical benefit response on patients Response is assessed using Response Evaluation Criteria in Solid Tumor Group RECIST guidelines Degree of response is used to divide the cancers into two groups sensitive and non-sensitive to immunotherapy
5 Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None